Journal of Clinical Medicine (Jun 2022)

Drugs and Vaccines Hypersensitivity in Children with Mastocytosis

  • Francesca Mori,
  • Giuseppe Crisafulli,
  • Annamaria Bianchi,
  • Paolo Bottau,
  • Silvia Caimmi,
  • Fabrizio Franceschini,
  • Lucia Liotti,
  • Claudia Paglialunga,
  • Francesca Saretta,
  • Carlo Caffarelli

DOI
https://doi.org/10.3390/jcm11113153
Journal volume & issue
Vol. 11, no. 11
p. 3153

Abstract

Read online

Mastocytosis, a heterogeneous mastcell disease, include three different entities: cutaneous mastocytosis, systemic mastocytosis (SM) and mast-cell sarcoma. Tryptase levels can differentiate cutaneous mastocytosis from SM. In mastocytosis, quick onset drug hypersensitivity reactions (DHRs) that are facilitated by mastcell mediators, are investigated in adults. Due to the limited number of children with mastcell disease and increased serum tryptase levels, the role of drugs in this age group is less studied. In this review, we critically assessed relevant papers related with immediate DHRs in children with mastocytosis and discuss practical issues of the management. In childhood mastocytosis, anaphylaxis is frequently idiopathic, and elevated level of basal tryptase, and high burden of disease may increase the risk. Among drugs, antibiotics, NSAIDs and opioids can potentially induce anaphylaxis, anyway avoidance should be recommended only in case of previous reactions. Moreover, vaccinations are not contraindicated in patients with mastocytosis. The risk of severe systemic reactions after drugs intake seems to be extremely low and in general lower in children than in adults. Anyway, studies on this topic especially focusing on children, are missing to state final recommendations.

Keywords